keyword
MENU ▼
Read by QxMD icon Read
search

Fibrosis AND Pirfenidone

keyword
https://www.readbyqxmd.com/read/28933986/the-antiangiogenesis-effect-of-pirfenidone-in-wound-healing-in-vitro
#1
Xiao'an Liu, Yangfan Yang, Xiujuan Guo, Liling Liu, Kaili Wu, Minbin Yu
Abstracts Background: Pirfenidone is mostly used in antifibrotic and anti-inflammatory therapies. We have previously demonstrated that pirfenidone had antifibrotic and anti-inflammatory effects on the wound healing process after glaucoma filtration surgery in vitro and in vivo. Since the wound healing and reactive scarring process simultaneously involves inflammation, fibrosis, and angiogenesis, and angiogenesis plays a more important role in chronic or prolonged wound healing, we tried to explore the antiangiogenesis effect in pirfenidone and its potential multitarget function in regulating excessive scarring...
September 21, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28933616/are-newly-launched-pharmacotherapies-efficacious-in-treating-idiopathic-pulmonary-fibrosis-or-is-there-still-more-work-to-be-done
#2
Riccardo Inchingolo, Carola Condoluci, Andrea Smargiassi, Annelisa Mastrobattista, Cristina Boccabella, Alessia Comes, Nicoletta Golfi, Luca Richeldi
Idiopathic pulmonary fibrosis (IPF) is a challenging and multifactorial disease that has been thought for some time to lack effective treatments. The approval of two drugs, nintedanib and pirfenidone, has heralded a new era in its management. Areas covered: Currently, there is a growing interest on therapeutic strategies. Many studies have been designed and performed, although few of them turned out to be successful. Nowadays, nintedanib and pirfenidone are considered disease modifying drugs, recommended treatments by current evidence-based guidelines...
September 21, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28932114/spermidine-mediated-poly-lactic-co-glycolic-acid-nanoparticles-containing-fluorofenidone-for-the-treatment-of-idiopathic-pulmonary-fibrosis
#3
Jing Tang, Jianming Li, Guo Li, Haitao Zhang, Ling Wang, Dai Li, Jinsong Ding
Idiopathic pulmonary fibrosis is a progressive, fatal lung disease with poor survival. The advances made in deciphering this disease have led to the approval of different antifibrotic molecules, such as pirfenidone and nintedanib. An increasing number of studies with particles (liposomes, nanoparticles [NPs], microspheres, nanopolymersomes, and nanoliposomes) modified with different functional groups have demonstrated improvement in lung-targeted drug delivery. In the present study, we prepared, characterized, and evaluated spermidine (Spd)-modified poly(lactic-co-glycolic acid) (PLGA) NPs as carriers for fluorofenidone (AKF) to improve the antifibrotic efficacy of this drug in the lung...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28921394/combination-therapy-with-pirfenidone-plus-prednisolone-ameliorates-paraquat-induced-pulmonary-fibrosis
#4
Rokhsana Rasooli, Fatemeh Pourgholamhosein, Younes Kamali, Fatemeh Nabipour, Ali Mandegary
Pirfenidone is known to slow the decline in vital capacity and increase survival in idiopathic pulmonary fibrosis (IPF). Besides, administration of glucocorticoids, e.g., prednisolone has been the conventional strategy to the treatment of patients with this disease, although their efficacy is under debate. Since multiple coactivated pathways are involved in the pathogenesis of IPF, combination therapy is a foundation strategy to cover many more synergetic mechanisms and increase response. The aim of the present study was to compare the therapeutic efficacy of prednisolone plus pirfenidone with pirfenidone alone in PQ-induced lung fibrosis...
September 18, 2017: Inflammation
https://www.readbyqxmd.com/read/28915874/unmet-needs-in-the-treatment-of-idiopathic-pulmonary-fibrosis-insights-from-patient-chart-review-in-five-european-countries
#5
Toby M Maher, Maria Molina-Molina, Anne-Marie Russell, Francesco Bonella, Stéphane Jouneau, Elena Ripamonti, Judit Axmann, Carlo Vancheri
BACKGROUND: Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis (IPF). In this analysis, treatment patterns of European patients with IPF were investigated to understand antifibrotic prescribing and identify unmet needs in IPF treatment practice. METHODS: Between February and March 2016, respiratory physicians from France, Germany, Italy, Spain, and the UK participated in an online questionnaire designed to collect information on IPF treatment patterns in patients under their care...
September 15, 2017: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/28898890/an-open-label-study-of-the-long-term-safety-of-pirfenidone-in-patients-with-idiopathic-pulmonary-fibrosis-recap
#6
Ulrich Costabel, Carlo Albera, Lisa H Lancaster, Chin-Yu Lin, Philip Hormel, Henry N Hulter, Paul W Noble
BACKGROUND: RECAP (NCT00662038) was an open-label extension study in patients with idiopathic pulmonary fibrosis (IPF) who completed either the Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) 016 phase 3 trial or the Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes (CAPACITY) 004/006 phase 3 trials. OBJECTIVE: To obtain long-term safety data for pirfenidone in patients with IPF in RECAP...
September 13, 2017: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/28892311/-how-i-treat-a-patient-with-idiopathic-pulmonary-fibrosis
#7
J Guiot, B Duysinx, O Bonhomme, R Louis, J-L Corhay
Idiopathic pulmonary fibrosis (IPF) is a rare disorder of unknown origin, which is associated with a high mortality and whose incidence has been increasing for several years. Nowadays there are two anti-fibrotic therapies (pirfenidone - nintedanib) known to reduce significantly the decline in respiratory function tests of patients suffering from this condition. The only curative therapeutic option remains the pulmonary transplantation whose accessibility remains limited. Pulmonary rehabilitation is also central in the treatment of patients...
September 2017: Revue Médicale de Liège
https://www.readbyqxmd.com/read/28889759/nintedanib-with-add-on-pirfenidone-in-idiopathic-pulmonary-fibrosis-results-of-the-injourney-trial
#8
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser, Wim A Wuyts
RATIONALE: Nintedanib and pirfenidone slow the progression of IPF, but the disease continues to progress. More data are needed on the safety and efficacy of combination therapy with nintedanib and add-on pirfenidone. OBJECTIVES: To investigate safety, tolerability, pharmacokinetic and exploratory efficacy endpoints in patients treated with nintedanib and add-on pirfenidone versus nintedanib alone. METHODS: Patients with IPF and FVC ≥50% predicted at screening who completed a 4-5 week run-in with nintedanib 150 mg bid without dose reduction or treatment interruption were randomized to nintedanib 150 mg bid with add-on pirfenidone (titrated to 801 mg tid), or nintedanib 150 mg bid alone, open-label for 12 weeks...
September 10, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28889145/efficacy-and-adverse-events-of-pirfenidone-in-treating-idiopathic-pulmonary-fibrosis
#9
Hui Ren, Kai Wang, Hao Yang, Lingyun Gao
To analyze the efficacy and adverse events  (AEs) of pirfenidone in idiopathic pulmonary fibrosis (IPF) trials. Methods: MEDLINE, Cochrane Library, and ClinicalTrials.gov were searched for studies published before June 2016. All studies of clinical trials with the key words IPF or idiopathic pulmonary fibrosis or lung fibrosis and pirfenidone or Esbriet were identified. Quality assessment and data extraction nwere conducted by 2 independent researchers. A meta-analysis of randomized controlled trials (RCTs) was performed, and relative risk (RR) and 95% confidence intervals (95% CIs) were calculated...
September 2017: Saudi Medical Journal
https://www.readbyqxmd.com/read/28877715/exploring-efficacy-and-safety-of-oral-pirfenidone-for-progressive-non-ipf-lung-fibrosis-relief-a-randomized-double-blind-placebo-controlled-parallel-group-multi-center-phase-ii-trial
#10
Jürgen Behr, Petra Neuser, Antje Prasse, Michael Kreuter, Klaus Rabe, Carmen Schade-Brittinger, Jasmin Wagner, Andreas Günther
BACKGROUND: Pirfenidone is currently approved in the EU for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) and offers a beneficial risk-benefit profile. However, there are several other, progressive fibrotic lung diseases, in which conventional anti-inflammatory therapy is not sufficiently effective and antifibrotic therapies may offer a novel treatment option. METHODS/DESIGN: We designed a study protocol for inclusion of patients with progressive fibrotic lung disease despite conventional anti-inflammatory therapy (EudraCT 2014-000861-32)...
September 6, 2017: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/28876508/the-effects-of-pirfenidone-in-patients-with-an-acute-exacerbation-of-interstitial-pneumonia
#11
Takuma Matsumura, Kenji Tsushima, Mitsuhiro Abe, Kenichi Suzuki, Kazutaka Yamagishi, Akane Matsumura, Yasunori Ichimura, Jun Ikari, Jiro Terada, Koichiro Tatsumi
Introdcution: The prognosis of patients with an acute exacerbation of interstitial pneumonia (AE-IP) is poor. Pirfenidone (PFD) reduces the disease progression in idiopathic pulmonary fibrosis. OBJECTIVES: The purpose of this study was evaluating whether the administration of PFD improved the outcomes of AE-IP. METHODS: We conducted a retrospective study of 31 patients with AE-IP who did not recover between 7 and 14 days after an initial treatment. Fourteen patients received PFD within 2 weeks (PFD group) of the AE, while 17 patients were treated without PFD (Non-PFD group)...
September 6, 2017: Clinical Respiratory Journal
https://www.readbyqxmd.com/read/28874823/role-of-smad3-and-p38-signalling-in-cigarette-smoke-induced-cftr-and-bk-dysfunction-in-primary-human-bronchial-airway-epithelial-cells
#12
Juliette Sailland, Astrid Grosche, Nathalie Baumlin, John S Dennis, Andreas Schmid, Stefanie Krick, Matthias Salathe
Mucociliary clearance (MCC) is a major airway host defence system that is impaired in patients with smoking-associated chronic bronchitis. This dysfunction is partially related to a decrease of airway surface liquid (ASL) volume that is in part regulated by apically expressed cystic fibrosis transmembrane conductance regulator (CFTR) and large-conductance, Ca(2+)-activated, and voltage dependent K(+) (BK) channels. Here, data from human bronchial epithelial cells (HBEC) confirm that cigarette smoke not only downregulates CFTR activity but also inhibits BK channel function, thereby causing ASL depletion...
September 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28869932/pirfenidone-in-idiopathic-pulmonary-fibrosis-recap-itulating-safety-into-the-real-world
#13
Argyris Tzouvelekis, Evangelos Bouros, Vasilios Tzilas, Demosthenes Bouros
No abstract text is available yet for this article.
September 5, 2017: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/28861727/managing-idiopathic-pulmonary-fibrosis-which-drug-for-which-patient
#14
Conal Hayton, Nazia Chaudhuri
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with high mortality. Two novel antifibrotic agents, pirfenidone and nintedanib, have received licences for use in IPF in recent years. Phase III, multinational, randomised control trials have provided evidence that both drugs reduce decline in forced vital capacity (FVC) over time, while further post hoc studies have suggested that both pirfenidone and nintedanib can be efficacious, regardless of age and severity of baseline lung function...
August 31, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28852519/fatal-diffuse-alveolar-haemorrhage-mimicking-acute-exacerbation-in-idiopathic-pulmonary-fibrosis-treated-with-nintedanib
#15
Keishi Sugino, Yasuhiko Nakamura, Muneyuki Sekiya, Hiroshi Kobayashi, Kazutoshi Shibuya, Sakae Homma
A 75-year-old man was referred to our hospital with a 1-year history of persistent dry cough and progressive dyspnoea on exertion. He was treated with aspirin due to thrombosis of internal carotid artery. He was diagnosed with idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP), and started on inhaled N-acetylcysteine therapy and pirfenidone. Since his clinical condition progressively deteriorated after 6 months, he was switched from pirfenidone to nintedanib. As a result, his general condition worsened rapidly...
November 2017: Respirology Case Reports
https://www.readbyqxmd.com/read/28845557/treatment-of-idiopathic-pulmonary-fibrosis-in-australia-and-new-zealand-a-position-statement-from-the-thoracic-society-of-australia-and-new-zealand-and-the-lung-foundation-australia
#16
Helen E Jo, Lauren K Troy, Gregory Keir, Daniel C Chambers, Anne Holland, Nicole Goh, Margaret Wilsher, Sally de Boer, Yuben Moodley, Christopher Grainge, Helen Whitford, Sally Chapman, Paul N Reynolds, Ian Glaspole, David Beatson, Leonie Jones, Peter Hopkins, Tamera J Corte
Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease (ILD) of unknown aetiology with a median survival of only 2-5 years. It is characterized by progressive dyspnoea and worsening lung function, ultimately resulting in death. Until recently, there were no effective therapies for IPF; however, with the publication of two landmark clinical trials in 2014, the anti-fibrotic therapies, nintedanib and pirfenidone, have gained widespread approval. This position paper aims to highlight the current evidence for the treatment of IPF, with particular application to the Australian and New Zealand population...
August 27, 2017: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/28843616/safety-and-efficacy-of-pirfenidone-in-severe-idiopathic-pulmonary-fibrosis-a-real-world-observational-study
#17
Argyrios Tzouvelekis, Paschalis Ntolios, Theodoros Karampitsakos, Vasilios Tzilas, Stavros Anevlavis, Evangelos Bouros, Paschalis Steiropoulos, Nikolaos Koulouris, Grigoris Stratakos, Marios Froudarakis, Demosthenes Bouros
BACKGROUND: Pirfenidone is a novel anti-fibrotic drug that has shown efficacy in five randomized multicenter clinical trials enrolling patients with Idiopathic Pulmonary Fibrosis of mild-to-moderate disease severity. Scarce data supports the use of pirfenidone in IPF patients with more advanced disease. OBJECTIVE: To investigate the safety and efficacy profile of pirfenidone in IPF patients with severe lung function impairment. PATIENTS AND METHODS: This was a retrospective study enrolling patients with advanced IPF (FVC%predicted < 50% and/or (DLco%predicted <35%) receiving pirfenidone for at least 6 months...
August 23, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28821135/exploring-pullulan-poly-vinyl-alcohol-interpenetrating-network-microspheres-as-controlled-release-drug-delivery-device
#18
Saundray Raj Soni, Animesh Ghosh
In the present study, interpenetrating polymeric network (IPN) microsphere was prepared using glutaraldehyde assisted water-in-oil emulsion crosslinking method for controlled delivery of pirfenidone, the only chemical entity approved by US FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF). In our study, the natural biopolymer pullulan was harnessed in combination with synthetic polymer PVA for drug delivery applications. The prepared microspheres were characterized by Fourier transform infrared spectroscopy, Raman spectroscopy, solid state (13)C nuclear magnetic resonance and field emission scanning electron microscopy...
October 15, 2017: Carbohydrate Polymers
https://www.readbyqxmd.com/read/28806504/designing-liposomes-to-suppress-extracellular-matrix-expression-to-enhance-drug-penetration-and-pancreatic-tumor-therapy
#19
Tianjiao Ji, Jiayan Lang, Jing Wang, Rong Cai, Yinlong Zhang, Feifei Qi, Lijing Zhang, Xiao Zhao, Wenjing Wu, Jihui Hao, Zhihai Qin, Ying Zhao, Guangjun Nie
During pancreatic tumor development, pancreatic stellate cells (PSCs) proliferate exuberantly to secrete extracellular matrix (ECM) in the tumor stroma, which presents major barriers for drug delivery and penetration in tumor tissue. Thus, down-regulating ECM levels via regulation of the PSCs may allow enhanced penetration of therapeutic drugs and thereby enhancing their therapeutic efficacy. To regulate the PSCs, a matrix metalloproteinase-2 (MMP-2) responsive peptide-hybrid liposome (MRPL) was constructed via co-assembly of a tailor-designed MMP-2 responsive amphiphilic peptide and phospholipids...
August 14, 2017: ACS Nano
https://www.readbyqxmd.com/read/28780989/idiopathic-pleuroparenchymal-fibroelastosis-ppfe-a-case-study-of-a-rare-entity
#20
E B Boerner, U Costabel, T E Wessendorf, D Theegarten, F Bonella
Idiopathic pleuroparenchymal fibroelastosis (IPPFE) was recognized as a rare new entity. We report the case of a 63 years old female suffering from progressive dyspnea and dry cough for three years. Two years before admission to our hospital, idiopathic pulmonary fibrosis (IPF) was diagnosed in another hospital and treatment with prednisolone and N-acetylcysteine (NAC) was commenced. At admission HRCT showed upper lobe dominant fibrosis and associated pleural thickening. Surgical biopsies were re-evaluated and revealed fibroelastosis with pleural thickening and a probable UIP pattern, consistent with idiopathic PPFE...
August 3, 2017: Revista Portuguesa de Pneumologia
keyword
keyword
98694
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"